MELISSA: Laser ion source setup at CERN-MEDICIS facility. Blueprint

Gadelshin, Vadim; Barozier, Vincent; Cocolios, T. E.; Fedosseev, V. N.; Formento-Cavaier, R.; Haddad, Férid; Marsh, B. A.; Marzari, S.; Rothe, S.; Stora, T.; Studer, Dominik; Weber, Felix; Wendt, Κ.

doi:10.1016/j.nimb.2019.04.024

Cited by 13 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MEDICIS' Laser Ion Source for Separator Assembly (MELISSA) ( 39 ) was utilized for the offline mass separation of 169 Er. 169 Er-containing ampoules were opened and transferred into an ISOLDE standard tantalum target container ( 25 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

et al. 2021

View full text Add to dashboard Cite

The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In the present work, an offline mass separation technique was used in combination with a resonance laser ion source ( 34 , 39 , 41 , 42 ), which ensured the increase of efficiency and selectivity for 169 Er. The activities produced were sufficient to perform one preliminary in vitro assay.…”

Section: Introductionmentioning

confidence: 99%

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A detailed description of the MELISSA setup is presented in [21]. In brief, it comprises an all-solid-state laser system, based on Ti:Sapphire lasers developed at Mainz University [22].…”

Section: Methodsmentioning

confidence: 99%

First laser ions at the CERN-MEDICIS facility

et al. 2020

View full text Add to dashboard Cite

The CERN-MEDICIS facility aims to produce emerging medical radionuclides for the theranostics approach in nuclear medicine with mass separation of ion beams. To enhance the radioisotope yield and purity of collected samples, the resonance ionization laser ion source MELISSA was constructed, and provided the first laser ions at the facility in 2019. Several operational tests were accomplished to investigate its performance in preparation for the upcoming production of terbium radioisotopes, which are of particular interest for medical applications.

show abstract

“…More information regarding the MEDICIS beam line can be found in (15). Furthermore, the MELISSA laser laboratory (16,17) helps to increase the separation efficiency and the selectivity. The extracted radionuclides are usually implanted onto thin zinccoated gold foils.…”

Section: Medicis' Modes Of Operation For Radionuclide Productionmentioning

confidence: 99%

“…It was followed by the successful commissioning of the shielded fume hood in March into which the collection foils can be safely removed from their support, and where radiochemistry developments can be performed. Another milestone was reached in 2019 when the MELISSA laboratory (16,17) became fully operational in April. The installed laser setup consisted of two Z-cavity Ti:sapphire lasers of the Mainz University/CERN design pumped by two 10 kHz pulsed Nd:YAG lasers InnoLas Nanio 532-18-Y (see Figure 6).…”

Section: : a Year Without Protons At Cern Compensated By The Use Of Externally Irradiated Target Materialsmentioning

confidence: 99%

CERN-MEDICIS: A Review Since Commissioning in 2017

Duchemin¹,

Ramos²,

Stora³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.

show abstract

MELISSA: Laser ion source setup at CERN-MEDICIS facility. Blueprint

Cited by 13 publications

References 10 publications

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

First laser ions at the CERN-MEDICIS facility

CERN-MEDICIS: A Review Since Commissioning in 2017

Contact Info

Product

Resources

About